Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo ClinicHolliston, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced that the first patient has been treated with its Cellspan™ Esophageal Implant (CEI) in the Company’s Phase 1 feasibility and safety clinical trial conducted at the Mayo Clinic in Rochester, Minnesota. This milestone represents a significant advancement in the Company’s clinical program and marks an important step toward offering patients a novel regenerative solution for esophageal disease.
Harvard Apparatus Regenerative Technology Collaborates with University of Southern California to Test Treatment for Esophageal DiseaseHOLLISTON, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company advancing a platform designed to regenerate tissue inside the body to restore organ function in severe disease, is proud to announce a new collaboration with University of Southern California (USC) to conduct a study of its Cellspan™ Esophageal Implant (CEI) product candidate. The collaboration will focus on clinical research and trial execution, including efficient patient identification and recruitment, with the goal of expanding access to potentially life-changing regenerative treatments.
